• ADVANZ PHARMA partners with Ashfield Engage to deliver talent acquisition strategy for European specialty medicine division

    Aug 20, 2021, 11:36 by
    Ashfield Engage, part of UDG Healthcare plc, announced that it has partnered with ADVANZ PHARMA to develop and deliver a pan-European talent acquisition programme for ADVANZ PHARMA’s specialty medicine division.
    Full story
  • Noxopharm Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer

    Aug 20, 2021, 11:36 by
    Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) has reported pre-clinical data confirming a survival benefit of adding Veyonda® to 177lutetium-PSMA-617 (LuPSMA) treatment in prostate cancer.
    Full story
  • Clinical Ink CBO Jonathan Andrus Selected as DTRA Co-Leader

    Aug 20, 2021, 11:36 by
    Clinical Ink, a global clinical trial technology company, today announced that CBO Jonathan Andrus has been selected to co-lead the Decentralized Trials & Research Alliance’s (DTRA) Initiative 4B: Collaborate on Regulatory Gaps.
    Full story
  • MicrobioSeq Division Releases Viral Metagenomics Services to Study Viruses

    Aug 20, 2021, 11:36 by
    Full story
  • Enveda Biosciences Boosts its Translational Capabilities with Two Key Hires

    Aug 20, 2021, 11:36 by
    Full story
  • Biotium Launches Optimized Solution for Exosome Detection by Flow Cytometry

    Aug 20, 2021, 11:36 by
    Biotium Launches Optimized Solution for Exosome Detection by Flow Cytometry
    Full story
  • The Time is Right to Disrupt Clinical Cancer Trials and Accelerate Innovation

    Aug 18, 2021, 01:00 by User Not Found
    Clinical Research News | As we prepare for a new decade, marked at its start by the astonishingly speedy development of a vaccine for COVID-19, clinical trial sponsors have the opportunity to disrupt the traditional drug development process like never before by using real-world data.
    Full story
  • Predicting Patient Response In COVID-19 Drug Trials

    Aug 16, 2021, 10:20 by User Not Found
    Clinical Research News | Based on cellular-level insights from previous COVID-19 clinical trials, mathematical modelers at the University of Waterloo (Ontario) have simulated how the body deals with the virus as a starting point for predicting how patients will respond to new experimental vaccines and treatments—including those targeting variants of concern. While this is a generic model meant to reflect an “average human being,” it can be customized to more precisely forecast drug effectiveness in individuals according to variables such as their gender, age, and comorbid conditions.
    Full story
  • An Application Now Rests with the FDA: How to Manage the Review Process

    Aug 13, 2021, 01:00 by User Not Found
    Clinical Research News | What is happening inside the FDA and the Center for Drug Evaluation and Research (CDER) statisticians in the review of the drug/device application? We look at what data are analyzed, the integrated review process, and labeling and post-approval evaluation.
    Full story
  • Ovarian Cancer Chip Model Reveals Drug Repurposing Opportunities

    Aug 11, 2021, 01:00 by User Not Found
    Clinical Research News | A novel organ-on-a-chip model of ovarian cancer has been used to showcase the sinister activities of tumors, including use of circulating platelets to fuel their growth and undermine treatment with chemotherapeutic drugs. The model also demonstrated the potential of an anti-platelet drug, currently in clinical trials for a different condition: to fight back.
    Full story
  • What You Don’t know, Will Hurt You: Overcoming “Missingness” in Healthcare Data

    Aug 6, 2021, 01:00 by User Not Found
    Clinical Research News | Most data sets—especially in healthcare—are missing data and, therefore, may not sufficiently representative to support the broader conclusions being drawn about groups of patients. Missing values is a problem that data scientists refer to as “missingness.” Even if data isn’t specifically missing, often the quality of the data is so poor that it is unusable and functionally considered missing. This missingness often leads directly to poor analytics outcomes.
    Full story
  • Follow the Money: Clinical Trial Platforms, Improving Diversity in Trials

    Aug 5, 2021, 01:00 by User Not Found
    Clinical Research News | Novartis and PCORI both invest in eliminating racial disparity in clinical research, 4G gets a big growth equity investment for randomization and trial supply management, ObvioHealth seeks to integrate the EHR for clinical trial design, and more.
    Full story
  • Parexel Acquisition, Medable Expands to Europe, NSF Funds for RWE Outcomes

    Aug 3, 2021, 01:00 by User Not Found
    Clinical Research News | Parexel acquired by private equity business, American Heart Association seeks genomic diversity, partnerships for Flywheel and HealthMyne as well as Marken and THREAD.
    Full story
  • Patient-Centric Focus, Awareness, Technology Can Fix Pharma’s Lack of Progress on Trial Diversity

    Jul 30, 2021, 01:00 by User Not Found
    Clinical Research News | Conversations of diversity in clinical trials has been just talk for a long time. It’s great that study results are being reported with demographic data about race and ethnicity, but it’s still up to the individual pharma company whether it wants to report diversity or not. This is not the path toward meaningful change.
    Full story
  • Machine Learning Can Predict If COVID-19 Trials Will Succeed

    Jul 29, 2021, 10:54 by User Not Found
    Clinical Research News | A pair of computer scientists at Florida Atlantic University have come up with a machine learning approach to predict the likelihood of a clinical trial being terminated down the road and attribute factors contributing to study termination or success. When applied to the flurry of COVID-19 trials launched since early last year it performs particularly well.
    Full story
  • Data Privacy And Patient-Centeredness Driving Technology Adoption

    Jul 26, 2021, 01:00 by User Not Found
    Clinical Research News | The potential of artificial intelligence (AI), internet-connected devices, wearables, and cloud computing to disrupt traditional clinical trials was explored during a presentation on patient-centered endpoints at the recent DIA 2021 Global Annual Meeting. The common goal is to make studies more palatable for participants, improving their engagement and retention, and to help pick up the pace and cost of making new medicines.
    Full story
  • 5 Reasons Why a Decentralized Method Works for Clinical Trials

    Jul 23, 2021, 01:00 by User Not Found
    Clinical Research News | With sponsors like IQVIA, Pfizer, and GSK joining the Decentralized Trials & Research Alliance and the FDA giving decentralization its nod of approval, it’s safe to say the clinical research industry will continue to embrace decentralized trials.
    Full story
  • Building Trust In Real-World Evidence

    Jul 21, 2021, 09:22 by User Not Found
    Clinical Research News | Lessons learned to date about the growing use of real-world evidence (RWE), including emerging approaches to improve study design and the measurement of treatment effects, were highlighted during a presentation by regulatory and pharmacoepidemiology (PE) experts at the recent DIA 2021 Global Annual Meeting. The wide-ranging conversation touched on everything from the regulatory context in which RWE is being used and whether clinical questions can be reliably addressed to the quality of real-world data (RWD) sources and more rigorous methodological approaches that might be adopted to help ensure confidence in study findings.
    Full story
  • Overcoming Barriers To Using Artificial Intelligence In Clinical Research

    Jul 20, 2021, 12:20 by User Not Found
    Clinical Research News | Current and potential uses of artificial intelligence (AI) and automation in clinical research, and ways to overcome common barriers, were discussed by a panel of industry experts at the recent DIA 2021 Global Annual Meeting. Two multi-stakeholder communities of practice groups now meet regularly to explore ways to leverage AI and machine learning (ML), one focused on improving trial quality and cycle times and the other producing high-quality protocols and reducing risks before the start of a study.
    Full story
  • MedVector To Connect Patients Of Local Physicians To Study Investigators

    Jul 19, 2021, 01:00 by User Not Found
    Clinical Research News | A startup is positioning itself to be a key player in the burgeoning decentralized clinical trial (DCT) marketplace and has tapped industry innovator Craig Lipset, who designed and co-led the industry’s first fully virtual clinical trial, to be its executive advisor. MedVector is the first company to enable local, non-investigative physicians to access clinical trial medications as a care alternative.
    Full story